N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]-4-pyrrolidin-1-ylbenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]-4-pyrrolidin-1-ylbenzamide
• 化学式: C₂₁H₂₃N₃O₃
• 分子量: 365.432
• InChiKey: JKVNVKOVLBVYHQ-KPKJPENVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  81.7
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-胺甲基苯甲醇 在 吡啶 4-二甲氨基吡啶 、 草酰氯 、 羟胺 、 1-羟基苯并三唑 、 二甲基亚砜 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙腈 为溶剂， 反应 2.0h， 生成 N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]-4-pyrrolidin-1-ylbenzamide
  参考文献：
  名称：

  Synthesis and Biological Evaluation of 3-(4-Substituted-phenyl)-N-hydroxy-2-propenamides, a New Class of Histone Deacetylase Inhibitors

  摘要：

  Inhibitors of histone deacetylases (HDACs) have been shown to induce differentiation and/or apoptosis of human tumor cells. Novel 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides have been prepared as a new class of HDAC inhibitors and evaluated for their antiproliferative activity and HDAC inhibitory activity. Incorporation of a 1,4-phenylene carboxamide linker, shown by 5, and a 4-(dimethylamino)phenyl or 4-(pyrrolidin-1-yl)phenyl group as a cap substructure generated highly potent hydroxamic acid-based HDAC inhibitors 5a and 5b.

  DOI：

  10.1021/jm030377q

文献信息

• [EN] alpha,beta-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS<br/>[FR] DERIVES D'ACIDE HYDROXAMIQUE DOLLAR G(A), DOLLAR G(B)-INSATURES ET LEUR UTILISATION COMME INHIBITEURS DE L'HISTONE DESACETYLASE
  申请人：SK CHEMICALS CO LTD

  公开号：WO2003087066A1

  公开（公告）日：2003-10-23

  Disclosed are agents that inhibit histone deacetylase. More specifically, the present invention relates to novel hydroxamic acid derivatives or pharmaceutically acceptable salts thereof for anticancer agents or other therapeutic agents based on their histone deacetylase inhibitory activity.

  揭示了抑制组蛋白去乙酰化酶的药剂。更具体地，本发明涉及新型羟基胺基酸衍生物或其药用盐，用作抗癌剂或其他治疗剂，基于它们对组蛋白去乙酰化酶的抑制活性。
• Alpha, beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors
  申请人：Kim Dae-Kee

  公开号：US20050124679A1

  公开（公告）日：2005-06-09

  Disclosed are agents that inhibit histone deacetylase. More specifically, the present invention relates to novel hydroxamic acid derivatives or pharmaceutically acceptable salts thereof for anticancer agents or other therapeutic agents based on their histone deacetylase inhibitory activity.

  本发明揭示了一种抑制组蛋白去乙酰化酶的药剂。更具体地说，本发明涉及一种新型的羟酰胺衍生物或其药学上可接受的盐，用作抗癌剂或其他治疗剂，基于它们的组蛋白去乙酰化酶抑制活性。
• Use of histone deacetylase inhibitors for enhancing immunotherapies
  申请人：Indiana University Research and Technology Corporation

  公开号：US10813919B2

  公开（公告）日：2020-10-27

  Compositions including combinations of class I histone deacetylase (HDAC) inhibitors and programmed cell death protein 1 (PD-1) inhibitors for enhancing antitumor activity are disclosed. Further disclosed are methods of administering these compositions as immunotherapies for suppressing regulatory T cells in renal cell carcinoma.

  本研究公开了包括I类组蛋白去乙酰化酶（HDAC）抑制剂和程序性细胞死亡蛋白1（PD-1）抑制剂的组合物，用于增强抗肿瘤活性。还公开了施用这些组合物作为免疫疗法以抑制肾细胞癌中调节性 T 细胞的方法。
• USE OF HISTONE DEACETYLASE INHIBITORS FOR ENHANCING IMMUNOTHERAPIES
  申请人：Indiana University Research and Technology Corporation

  公开号：US20190030011A1

  公开（公告）日：2019-01-31

  Compositions including combinations of class I histone deacetylase (HDAC) inhibitors and programmed cell death protein 1 (PD-1) inhibitors for enhancing antitumor activity are disclosed. Further disclosed are methods of administering these compositions as immunotherapies for suppressing regulatory T cells in renal cell carcinoma.
• US7495022B2
  申请人：——

  公开号：US7495022B2

  公开（公告）日：2009-02-24